Abstract 232P
Background
An ongoing field of research examines the use of the proteasome genes as prognostic biomarkers in cancer. The cross talk between such machinery and VHL is well rectified, so it is of a great interest to study the prognostic utility of the 20S proteasome gene family in VHL-mutated ccRCC cohort.
Methods
Clinical and transcriptomics data of VHL-mutated ccRCC patients were obtained from the Cancer Genome Atlas Program (TCGA). A total of 11 genes of the 20S proteasome β-subunit (PSMB1-11) were retrieved and tested for their prognostic potential using multivariate Cox logistic regression. The immune suppressive landscape was viewed through the assessment of M2 macrophages (M2M), cancer-associated fibroblasts (CAF), T-regulatory cells (Tregs), and myeloid-derived suppressor cells (MDSC) infiltration using xCell. Correlations with T-cell exhaustion genes were performed additionally.
Results
A total of six genes exhibited significant prognostic indicators, including PSMB1 (HR: 2.113, 95% CI: 1.101-4.056, P = .024), PSMB2 (HR: 2.303, 95% CI: 1.168-4.542, P = .016), PSMB4 (HR: 2.165, 95% CI: 1.075-4.361, P = .031), PSMB6 (HR: 2.956, 95% CI: 1.458-5.998, P = .003), PSMB7 (HR: 2.168, 95% CI: 1.127-4.170, P = .020), and PSMB10 (HR: 2.227, 95% CI: 1.109-4.469, P = .024). Immunosuppressive cells infiltration analysis revealed the following significant correlations (P < .05): PSMB1: MDSC (ρ = 0.316), PSMB2: M2M (ρ = 0.242) and MDSC (ρ = 0.268), PSMB4: M2M (ρ = 0.159) and MDSC (ρ = 0.372), PSMB6: M2M (ρ = 0.247) and MDSC (ρ = 0.412), PSMB7: MDSC (ρ = 0.298), and PSMB10: M2M (ρ = 0.283) and MDSC (ρ = 0.271). No significant correlations were observed in CAF infiltration. Surprisingly, all the markers negatively correlated with Tregs infiltration. The prognostic genes followed a unified pattern of correlation with T-cell exhaustion genes in which positive significant correlations to CTLA4, LAG3, and GZMB were observed. In contrast, all the markers negatively correlated with CD274 (PD-L1) expression.
Conclusions
Several members of the 20S proteasome β-subunit gene family exhibit a prognostic role in VHL-mutated ccRCC and induce an immunosuppressive tumor microenvironment.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
497P - Sintilimab in combination with anlotinib in advanced NSCLC treated with first-line PD-1 antibodies: An open, single-arm, phase II trial
Presenter: Ying Jin
Session: Poster Display
Resources:
Abstract
498P - Frailty-adjusted life expectancy and survival in older lung cancer patients: A large-scale electronic health-record based study
Presenter: Thao Tu
Session: Poster Display
Resources:
Abstract
499P - Long-term survival and treatment (tx) patterns after first-line (1L) osimertinib in patients (pts) with epidermal growth factor receptor (EGFR) mutation-positive (m) advanced non-small cell lung cancer (NSCLC): Japanese cohort of a global real-world (rw) observational study
Presenter: Daichi Fujimoto
Session: Poster Display
Resources:
Abstract
500P - The effectiveness and safety of durvalumab after chemoradiotherapy for locoregional recurrence of completely resected non-small cell lung cancer: Real-world, multicenter, observational study (NEJ056)
Presenter: Hidehito Horinouchi
Session: Poster Display
Resources:
Abstract
501P - One-year survival outcomes of unresectable stage III non-small cell lung cancer patients who underwent PD-1 inhibitor plus chemo as induction therapy
Presenter: Xin Wang
Session: Poster Display
Resources:
Abstract
502P - Impact of sarcopenia on the outcome of patients with locally advanced non-small cell lung cancer treated with chemoradiotherapy followed by durvalumab
Presenter: Kentaro Tamura
Session: Poster Display
Resources:
Abstract
503P - Clinical outcomes by infusion timing of immune checkpoint inhibitors in patients with locally advanced NSCLC
Presenter: TSUYOSHI HIRATA
Session: Poster Display
Resources:
Abstract
504P - Real-world outcomes with induction systemic therapy for stage III in eligible for upfront local therapy: Pre vs post immunotherapy era in a tertiary referral centre
Presenter: Praveen Kumar Marimuthu
Session: Poster Display
Resources:
Abstract
505P - Neoadjuvant PD-1 inhibitor (tislelizumab) plus platinum–etoposide in patients with limited-stage small cell lung cancer: A phase II trial
Presenter: Junjie Hu
Session: Poster Display
Resources:
Abstract
506P - Intrathoracic progression is still the most dominant failure pattern after first-line chemo-immunotherapy in extensive-stage small-cell lung cancer: Implications for thoracic radiotherapy
Presenter: Byoung Hyuck Kim
Session: Poster Display
Resources:
Abstract